Photodynamic therapy in oncology

Bibliography

• RAAB O: Deber die Wirkung Fluorescierender Stoffe aut Infusoria. Journal Biology (1990) 39:524.
   Google Scholar
• LIPSON RL, GRAY MJ, BALDES EJ: Hematoporphyrin derivative for Detection and Management of Cancer. Proceeding of the 9th International Cancer Congress. Tokyo (1966)393.
   Google Scholar
• KELLY JF, SNELL ME: Hematoporphyrin Derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. Urol . (1976) 115(2):150–151.
   Google Scholar
• DOUGHERTY TJ: Photodynamic therapy. Photochem. PhotobioL (1993) 58(6):895–900.
   PubMed Web of Science ®Google Scholar
• BAAS P, MURRER L, ZOETMULDER FA et al.: Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br. J. Cancer (1997) 76(6):819–826.
   PubMedGoogle Scholar
• DOUGHERTY TJ, GOMER CJ, HENDERSON BW et al.: Photodynamic therapy. j Natl. Cancer Inst. (1998) 90(12):889–905.
   PubMed Web of Science ®Google Scholar
• COLUSSI VC, FEYES DK, MUKHTAR H: Perspectives of photodynamic therapy for skin diseases. Skin PharmacoL AppL Skin PhysioL (1998) 11(6):336–346.
   PubMedGoogle Scholar
• MOSER JG: 2nd and 3nd Generation Photosensitizers. Harwood, Amsterdam (1998).
   Google Scholar
• PATTERSON MS, WILSON BC: Photodynamic Therapy. In: The Modern Technology of Radiation Oncology Dyh JV (Ed.) Madison, Medical Physics Publishing, Madison (1999):941–980.
   Google Scholar
• SIBATA CH, COLUSSI VC, OLEINICK NL, KINSELLA TJ: Photodynamic therapy: a new concept in medical treatment. Braz J. Med. Biol. Res. (2000) 33(8):869–880.
   PubMed Web of Science ®Google Scholar
• FOOTE CS: Definition of type land type II photosensitized oxidation. Photochem. PhotobioL (1991) 54(5):659.
   PubMed Web of Science ®Google Scholar
• ZAIDI SI, OLEINICK NL, ZAIM MT, MUKHTAR H: Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem. PhotobioL (1993) 58(6):771–776.
   PubMedGoogle Scholar
• COLUSSI VC, FEYES DK, MULVIHILL JW et al.: Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts. Photochem. PhotobioL (1999) 69(2):236–241.
   PubMedGoogle Scholar
• AGARWAL R, KORMAN NJ, MOHAN RR et al.: Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin. Photochem. PhotobioL (1996) 63(4):547–552.
   PubMedGoogle Scholar
• WEBBER J, LUO Y, CRILLY R, FROMM D, KESSEL D: An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. Photochem. PhotobioL B. (1996) 35(3):209–211.
   PubMedGoogle Scholar
• ZHOU C, SHUNJI C, JINSHENG D, JUNLIN L, JORI G, MILANESI C: Apoptosis of mouse MS-2 fibrosarcoma cells induced by photodynamic therapy with Zn (II)-phthalocyanine. Photochem. PhotobioL B. (1996) 33(3):219–223.
   PubMedGoogle Scholar
• OLEINICK NL, EVANS HH: The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat. Res. (1998) 150(5 Suppl):5146–156.
   Google Scholar
• KIM HR, LUO Y, LI G, KESSEL D: Enhanced apoptotic response to photodynamic therapy after bc1-2 transfection. Cancer Res. (1999) 59(14):3429–3432.
   PubMedGoogle Scholar
• XUE L-Y, CHIU S-M, OLEINICK NL: Photochemical destruction of the Bc1-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene (2001). (In Press).
   Google Scholar
• OLEINICK NL, MORRIS RL, BELICHENKO I: Apoptosis in response to photodynamic therapy: What, where, why, and how. I Photochem. PhotobioL B. (2001) (Submitted for publication).
   Google Scholar
• MOOR AC: Signaling pathways in cell death and survival after photodynamic therapy. I Photochem. PhotobioL B. (2000) 57(1):1–13.
   PubMedGoogle Scholar
• FISHER AM, FERRARIO A, RUCKER N, ZHANG S, GOMER CJ: Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Res. (1999) 59(2):331–335.
   PubMedGoogle Scholar
• HE J, AGARWAL ML, LARKIN HE, FRIEDMAN LR, XUE LY, OLEINICK NL: The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2. Photochem. PhotobioL (1996) 64(5):845–852.
   PubMedGoogle Scholar
• GRANVILLE DJ, JIANG H, AN MT, LEVY JG, MCMANUS BM, HUNT DW: Bc1-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br Cancer (1999) 79(1):95–100.
   Google Scholar
• GRANVILLE DJ, JIANG H, AN MT, LEVY JG, MCMANUS BM, HUNT DW: Overexpression of Bc1-X(L) prevents caspase-3-mediated activation of DNA fragmentation factor (DFF) produced by treatment with the photochemotherapeutic agent BPD-MA. FEBS Lett. (1998) 422(2):151–154.
   PubMedGoogle Scholar
• XUE LY, CHIU SM, OLEINICK NL: Photodynamic therapy-induced death of MCF-7 human breast cancer cells: a role for caspase-3 in the late steps of apoptosis but not for the critical lethal event. Exp. Cell. Res. (2001) 263(1):145–55.
   PubMedGoogle Scholar
• PENG Q, MOAN J, NESLAND JM: Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. PathoL (1996) 20(2):109–129.
   PubMed Web of Science ®Google Scholar
• GOLLNICK SO, LIU X, OWCZARCZAK B, MUSSER DA, HENDERSON BW: Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. (1997) 57(18):3904–3909.
   PubMed Web of Science ®Google Scholar
• KORBELIK M: Induction of tumor immunity by photodynamic therapy. Clin. Laser Med. Surg. (1996) 14(5):329–334.
   PubMedGoogle Scholar
• KORBELIK M, DOUGHERTY GJ: Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res.(1999) 59(8):1941–1946.
   PubMedGoogle Scholar
• REDDAN JC, ANDERSON CY, XU H et al.: Immunosuppressive effects of silicon phthalocyanine photodynamic therapy. Photochem. PhotobioL (1999) 70(1):72–77.
   PubMedGoogle Scholar
• MACDONALD IJ, MORGAN J, BELLNIER DA et al.: Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives. Photochem. PhotobioL (1999) 70(5):789–797.
   PubMedGoogle Scholar
• MCCAUGHAN JS: Photodynamic Therapy of Malignancies: A Clinical Manual. Austin RG (Ed.), Lander Company (1972).
   Google Scholar
• EICHLER HG, MULLER M: Drug distribution. The forgotten relative in clinical pharmacokinetics. CBI]. Pharmacokinet. (1998) 34(2):95–99.
   PubMedGoogle Scholar
• COLUSSI VC, FEYES DK, MOURANT JR et al.: Determination of Phthalocyanine 4 (Pc 4) Concentration in Tissue by a New Non-Invasive, Site-Specific Spectroscopic Device. j Photochem. Photobiol B. (2001).
   Google Scholar
• MOURANT JR, JOHNSON TM, LOS G,BIGIO IJ: Non-invasive measurement of chemotherapy drug concentrations in tissue: preliminary demonstrations of in vivo measurements. Phys. Med. Biol. (1999) 44(5):1397–1417.
   PubMedGoogle Scholar
• PATTERSON MS, WILSON BC, FEATHER JW, BURNS DM, PUSHKA W: The measurement of dihematoporphyrin ether concentration in tissue by reflectance spectrophotometry. Photochem. Photobiol (1987) 46(3):337–343.
   PubMed Web of Science ®Google Scholar
• WEERSINK RA, HAYWARD JE, DIAMOND KR, PATTERSON MS: Accuracy of noninvasive in vivo measurements of photosensitizer uptake based on a diffusion model of reflectance spectroscopy. Photochem. Photobiol (1997) 66(3):326–335.
   PubMedGoogle Scholar
• VAN DEN BERGH H: On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy (1998) 30(4):392–407.
   PubMedGoogle Scholar
• COLUSSI VC, MULVIHILL JW, KINSELLA TJ, SIBATA CH: Film Dosimetry for Quantitative Flatness and Symmetry of Light Irradiation Devices Used in Photodynamic Therapy. Proceeding of the World Congress on Medical Physics and Biomedical Engineering: 42nd Annual Meeting of the American Association of Physics in Medicine. AAPM, Chicago (2000):27.
   Google Scholar
• MOAN J, SOMMER S: Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res. (1985) 45(4):1608–1610.
   PubMedGoogle Scholar
• TROMBERG BJ, ORENSTEIN A, KIMEL S et al.: In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem. Photobiol (1990) 52(2):375–385.
   PubMedGoogle Scholar
• CHEN Q, CHEN H, SHAPIRO H, HETZEL FW: Sequencing of combined hyperthermia and photodynamic therapy. Radiat. Res. (1996) 146(3):293–297.
   PubMedGoogle Scholar
• JIRSA M, JR., POUCKOVA P, DOLEZALJ, POSPISIL J, JIRSA M: Hyperbaric oxygen and photodynamic therapy in tumour-bearing nude mice. Eur j Cancer (1991)27(1):109.
   PubMedGoogle Scholar
• NICOLA JH, COLUSSI VC, NICOLA EMD, METZE K: Enhancement of Photodynamic Therapy due to Hyperbaric Hyperoxia: An experimental study of Walker 256 tumors in rats. Proceeding of the SP/E2972:88-94. In: Optical methods for Tumot Treatment and detection: Mechanisms and techniques in Photodynamic Therapy VI, Dougherty TJ (Ed.) San Jose, California USA (1997).
   Google Scholar
• FISHER AM, MURPHREE AL, GOMER CJ: Clinical and preclinical photodynamic therapy. Lasers Surg. Med. (1995) 17(1):2–31.
   PubMedGoogle Scholar
• KENNEDY JC, POTTIER RH: Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. j Photochem. Photobiol B. (1992) 14(4):275–292.
   PubMed Web of Science ®Google Scholar
• SPIKES JD: Chlorins as photosensitizers in biology and medicine. j Photochem. Photobiol B. (1990) 6(3):259–274.
   PubMedGoogle Scholar
• BEN-HUR E, ROSENTHAL I: The Phthalocyanines: a new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int. I Radial Biol. Relat. Stud. Phys. Chem. Med. (1985) 47(2):145–147.
   PubMed Web of Science ®Google Scholar
• OLEINICK NL, ANTUNEZ AR, CLAY ME, RIHTER BD, KENNEY ME: New phthalocyanine photosensitizers for photodynamic therapy. Photochem. Photobiol (1993) 57(2):242–247.
   PubMedGoogle Scholar
• ALLEN CM, SHARMAN WM, VAN LIER JE: Current Status of phthalocyanines in the photodynamic therapy of cancer. I Porphyrins Phthalocyanines (2001) 5:161–169.
   Web of Science ®Google Scholar
• PASS HI: Photodynamic therapy in oncology: mechanisms and clinical use. Natl. Cancer BBL (1993) 85(6):443–456.
   PubMedGoogle Scholar
• DIWU Z, LOWN JW: Phototherapeutic potential of alternative photosensitizers to porphyrins. Pharmacol Ther. (1994) 63(1):1–35.
   PubMedGoogle Scholar
• KREIMER-BIRNBAUM M: Modified porphyrins, chlorins, phthalocyanines, and purpurins: second-generation photosensitizers for photodynamic therapy. Semin. Hematol (1989) 26(2):157–173.
   PubMedGoogle Scholar
• LIGHTDALE CJ, HEIER SK, MARCON NE et al.: Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Castrointesl Endow. (1995) 42(6):507–512.
   PubMed Web of Science ®Google Scholar
• KATO H: [History of photodynamic therapy--past, present and future]. Can To Kagaku Ryoho (1996) 23(1):8–15.
   PubMedGoogle Scholar
• OVERHOLT BF, PANJEHPOUR M: Photodynamic therapy in the management of Barrett's esophagus with dysplasia. I Castrointest. Surg. (2000) 4(2):129–130.
   PubMedGoogle Scholar
• PANJEHPOUR M, OVERHOLT BF, HAYDEK JM, LEE SG: Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am. j Castroenterol (2000) 95(9):2177–2184.
   PubMed Web of Science ®Google Scholar
• OVERHOLT BF, PANJEHPOUR M: Photodynamic therapy in Barrett's esophagus. I Clin. Laser Med. Surg. (1996) 14(5):245–249.
   PubMedGoogle Scholar
• BIEL MA: Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope (1998) 108(9):1259–1268.
   PubMedGoogle Scholar
• ALLISON RR, MANG TS, WILSON BD: Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin. Cutan. Med. Surg. (1998) 17(2):153–163.
   PubMed Web of Science ®Google Scholar
• TABER SW, FINGAR VH, WIEMAN TJ: Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. I Surg. arca (1998) 68(4):209–214.
   Google Scholar
• SPERDUTO PW, DELANEY TF, THOMAS G et al.: Photodynamic therapy for chest wall recurrence in breast cancer. Int. I Radial arca Biol. Phys. (1991) 21(2):441–446.
   PubMedGoogle Scholar
• BERNSTEIN ZP, WILSON BD, OSEROFF AR et al: Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. Aids (1999) 13(13):1697–1704.
   PubMed Web of Science ®Google Scholar
• POPOVIC EA, KAYE AH, HILL JS: Photodynamic therapy of brain tumors. Clin. Laser Med. Surg. (1996) 14(5):251–261.
   PubMedGoogle Scholar
• MARKS PV, BELCHETZ PE, SAXENA Aet al.: Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase trial--an early report. Br. I Neurosurg. (2000) 14(4):317–325.
   Google Scholar
• TAKITA H, MANG TS, LOEWEN GM et al.: Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann. Thorac. Surg. (1994) 58(4):995–998.
   PubMedGoogle Scholar
• HENDREN SK, HAHN SM, SPITZ FR et al.: Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann. Surg. arca (2001) 8(1):65–71.
   Google Scholar
• PENG Q, WARLOE T, BERG K et al.: 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer (1997) 79(12)2282–2308.
   Google Scholar
• GOSSNER L, SROKA R, HAHN EG, ELL C: Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. Castrointest. Enclose. (1995) 41(1):55–58.
   PubMedGoogle Scholar
• PENG Q, BERG K, MOAN J, KONGSHAUG M, NESLAND JM: 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. PhotobioL (1997) 65(2):235–251.
   PubMed Web of Science ®Google Scholar
• GRANT WE, HOPPER C, MACROBERT AJ: Photodynamic Therapy of Oral Cancer: Photosensitization with systemic aminolevulinic acid. Lancet (1993) 342:147–148.
   PubMed Web of Science ®Google Scholar
• LOH CS, MACROBERT AJ, BEDWELL J, REGULA J, KRASNER N, BOWN SG: Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. Br. J. Cancer (1993) 68(1):41–51.
   PubMedGoogle Scholar
• MLKVY P, MESSMANN H, REGULA J et al.: Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. Neoplasma (1995) 42(3):109–113.
   PubMedGoogle Scholar
• REGULA J, MACROBERT AJ, GORCHEIN A et al.: Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. Cut (1995) 36(1):67–75.
   Google Scholar
• LANGE N, JICHLINSKI P, ZELLWEGER M etal.: Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br Cancer (1999) 80(1–2):185–193.
   Google Scholar
• GREKIN RJ, RAZUN N, TROMMER R, DORTON D, SNYDER A: Tin ethyl etiopurpurin (SnET2) photodynamic therapy (PDT): Results of a Phase I/II clinical study conducted at UCSF for the treatment of AIDS-associated cutaneous Kaposi's sarcomas. Proceedings of the International Conference on AIDS (1996) 11:98
   Google Scholar
• SELMAN SH, KECK RW, HAMPTON JA: Transperineal photodynamic ablation of the canine prostate. j Ural. (1996) 156(1):258–260.
   PubMedGoogle Scholar
• MANG TS, ALLISON R, HEWS ON G, SNIDER W, MOSKOWITZ R: A phase II/ III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer j Sci. Am. (1998) 4(6):378–384.
   PubMedGoogle Scholar
• KAPLAN MJ, SOMERS RG, GREENBERG RH, ACKLER J: Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). I Surg. arca (1998) 67(2):121–125.
   Google Scholar
• GROSJEAN P, SAVARY JF, MIZERET J et al.: Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyfi chlorin. j Clin. Laser Med. Surg. (1996) 14(5):281–287.
   PubMedGoogle Scholar
• RONN AM, LOFGREN LA, WESTBORN KM: Interspecies Pharmacokinetics as applied to the ''hard drug photosensiting agent meta (tetrahydroxylchlorin). Proceeding of the International Soc. Optical Engineering (1995) 2625:118–123.
   Google Scholar
• LUI H: Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Serail]. Oricol (1994) 21(6 Suppl 15):11–14.
   Google Scholar
• YOUNG LH, HOWARD MA, HU LK, KIM RY, GRAGOUDAS ES: Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch. OphthalmoL (1996) 114(2):186–192.
   PubMed Web of Science ®Google Scholar
• MOMMA T, HAMBLIN MR, WU HC, HASAN T: Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. (1998) 58(23):5425–5431.
   PubMedGoogle Scholar
• SESSLER JL, MILLER RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem. PharmacoL (2000) 59(7):733–739.
   PubMed Web of Science ®Google Scholar
• RENSCHLERMF, YUEN A, PANELLA TJ etal. Photodynamic Therapy Trials with Lutetium Texaphyrin PCI-0123 (Lu-Tex). Proceeding of the 25th Annual Meeting for Photobiology The American Society for Photobiology St. Louis, MO, USA (1997) 65:47S.
   Google Scholar
• HAMMER-WILSON MJ, GRAHRAMANLOU M, BERNS MW: Photodynamic activity of lutetium-texaphyrin in a mouse tumor system. Lasers Surg. Med. (1999) 24(4):276–284.
   PubMedGoogle Scholar
• TABER SW, FINGAR VH, COOTS CT, WIEMAN TJ: Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Chia. Cancer Res. (1998) 4(10:2741–2746.
   PubMedGoogle Scholar
• ANDERSON CY, FREYE K, TUBESING KA et al.: A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice. Photochem. PhotobioL (1998) 67(3):332–336.
   PubMedGoogle Scholar
• TAKITA H, DOUGHERTY TJ: Intracavitary photodynamic therapy for malignant pleural mesothelioma. Semin. Surg. arca (1995) 11(5):368–371.
   PubMedGoogle Scholar
• OVERHOLT BF, PANJEHPOUR M, HAYDEK JM: Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Castrointest. Enclose (1999) 49(1):1–7.
   PubMed Web of Science ®Google Scholar
• DELANEY TF, SINDELAR WF, TOCHNER Z etal.: Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Irk. j Radiat. arca Biol. Phys. (1993) 25(3):445–457.
   Google Scholar
• ALLISON R, MANG T, HEWSON G, SNIDER W, DOUGHERTY D: Photodynamic therapy for chest wall progression from breast carcinoma is an underutilized treatment modality. Cancer (2001) 91(1):1–8.
   PubMed Web of Science ®Google Scholar
• JICHLINSKI P, MIZERET J, FORRER M et al.: [Superficial bladder tumors. Pathological and clinical review and presentation of a new diagnostic method: fluorescence photodetection of transitional epithelial carcinomas based on protoporphyrin IX induction with delta-aminolevulinic acid (5-ALA)1. Rev Med. Suisse. Romande (1995) 115(3):233–237.
   Google Scholar
• JONES CM, MANG T, COOPER M, WILSON BD, STOLL HL, Jr.: Photodynamic therapy in the treatment of Bowen's disease. j Am. Acad. Dermatol (1992) 27(6 Pt 1):979–982.
   Google Scholar
• SELMAN SH, KREIMER-BIRNBAUM M, CHAUDHURI K et al.: Photodynamic treatment of transplantable bladder tumors in rodents after pretreatment with chloroaluminum tetrasulfophthalocyanine. Urel . (1986) 136(1):141–145.
   PubMedGoogle Scholar
• NSEYO UO, DEHAVEN J, DOUGHERTY TJ et al.: Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. j Clio. Laser Med. Sorg. (1998) 16(1):61–68.
   PubMedGoogle Scholar
• WOODBURN KW, FAN Q, KESSEL D, LUO Y, YOUNG SW: Photodynamic therapy of Bl6F10 murine melanoma with lutetium texaphyrin. I Invest. Dermata (1998) 110(5):746–751.
   PubMedGoogle Scholar